Charles Warden
Managing Director @ Versant Ventures
Burlingame, United States
Charles Warden is a funding round investor at Versant Ventures in Burlingame focused on Health Care and Biotechnology. Charles Warden - Managing Director @ Versant Ventures
- Total investments:
- 14
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Charles Warden invests in
Stages Charles Warden invests in
Countries Charles Warden invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 6 (43%)
- Biotechnology 4 (29%)
- Medical Device 4 (29%)
- Medical 2 (14%)
- Pharmaceutical 1 (7%)
Stage
- Funding Round 3 (21%)
- Series B 2 (14%)
- Series C 2 (14%)
- Debt Financing 2 (14%)
- Series D 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons onsurgical placement of the KAMRA.It was founded in 2011 and headquartered in Irvine, California. | $21M / Series G / Sep 03, 2014 | ||
| Ceterix Orthopaedics, Inc. develops novel surgical tools for arthroscopic procedures. The Ceterix technology enables surgeons to place stitches in very tight joint compartments, while protecting sensitive surrounding structures such as nerves, arteries and cartilage. This technology has applications in numerous arthroscopic procedures in knees,hips and shoulders.Ceterix was established in October 2010. The company was founded based on the inventions of Dr. Justin Saliman, an orthopaedic surgeon specializing in sports medicine. Dr. Saliman envisioned improving the outcomes of arthroscopic procedures by enabling surgeons to place suture patterns that today can be done only in open procedures, if at all. Ceterix is based in Menlo Park, California. | $18M / Series B / May 13, 2014 | ||
| Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic andbiocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma. | $23.8M / Series D / Jun 10, 2013 | ||
| GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California. | $5.6M / Debt Financing / Jan 01, 2013 | ||
| HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such asfibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia. | $4.3M / Debt Financing / Jun 28, 2012 | ||
| GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California. | $13.3M / Mar 15, 2012 | ||
| Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons onsurgical placement of the KAMRA.It was founded in 2011 and headquartered in Irvine, California. | $65M / Private Equity / Nov 29, 2011 | ||
| HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such asfibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia. | $3.5M / Apr 20, 2011 | ||
| Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic andbiocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma. | $14M / Series D / Feb 03, 2011 | ||
| Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic andbiocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma. | $6M / Series C / Jan 12, 2011 | ||
| See all 14 investments → | |||
Co-Investors
About Versant Ventures
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and officesin Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Versant Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Charles Warden
Managing Director
|
|||
Clare Ozawa
Managing Director
|
|||
Donald Milder
Managing Director
|
|||
Gianni Gromo
Partner
|
|||
Guido Magni
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Charles Warden invest in?
Charles Warden invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Funding Round and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Charles Warden?
Public channels for Charles Warden include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Charles Warden last invest?
The most recent investment recorded for Charles Warden closed in Sep 2014. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
